Infection with Mycobacterium tuberculosis (MTB) remains one of the most challenging infectious disease problems worldwide. In most individuals the MTB infection is initially contained by the host's immune defence and remains latent. The World Health Organization (WHO) estimates that one-third of the world's population is latently infected with MTB. The main method for LTBI diagnosis has been the tuberculin skin test (TST). The TST is based on a delayed-type hypersensitivity reaction after stimulation with tuberculin purified protein derivate (PPD). Tuberculin PPD contains a broad range of cross-reactive antigens recognised both after bacille Calmette-Guérin (BCG) vaccination and after infection with MTB or non-tuberculous mycobacteria. 11,12 TST positivity is clearly associated with subsequent risk of developing active TB disease and has been used for decades to screen for LTBI. [13] [14] [15] The major downfalls are the impaired specificity due to cross-reactivity 11,12 and impaired sensitivity, especially in HIV-co-infected individuals. 9, [16] [17] [18] [19] [20] Furthermore, the TST lacks an internal control to distinguish false-negative results due to anergy from true negative results, leading to a poor diagnostic accuracy, especially in HIVpositive individuals, due to a high rate of unresponsiveness.
The development of new interferon-gamma (IFN-γ) release assays (IGRAs) is a promising attempt to overcome the problems with specificity and sensitivity. [21] [22] [23] [24] Two IGRAs are now commercially available: the T.Spot TB ® (Oxford Immunotech, UK) (T-Spot), and the QuantiFERON-TB gold ® and QuantiFERON-TB gold InTube ® (Cellestis, Australia) (QFT and QFT-IT, respectively). Both tests are based on ex vivo stimulation of T cells in either whole blood (QFT) or purified lymphocytes (T-spot) with MTB-specific antigens followed by quantification of IFN-γ using enzyme-linked immunosorbent assay (ELISA) or enzyme-linked immunosorbent spot (ELISPOT) technology.
The 6kDa early secretory antigenic target (ESAT-6) and culture filtrate protein 10 (CFP-10), used for stimulation, are encoded in the region of deletion (RD) 1, which is absent from the BCG vaccine strain [25] [26] [27] and most non-tuberculous mycobacteria. 21, 28 The QFT-IT includes an additional specific epitope, TB7.7p4, and an optimised cell stimulation system based on vacutainer tubes pre-coated with the peptides, ensuring the immediate stimulation of T cells once the blood is drawn.
IGRAs measure the TB-specific effector/memory T-cell responses directly ex vivo by their IFN-γ secretory capacity.
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Advantages and Limitations of Interferon-gamma Release Assays in HIV-positive Individuals
The obvious advantages of the IGRAs are that they are specific for MTB infections with hardly any cross-reactivity. The pooled specificity of the T-spot in healthy unexposed individuals was 97.7% (95% confidence interval [CI] 96-99%) and all QFT formats 92.5% (95% CI 86-99%). 22 As a further advantage, IGRAs contain an internal positive control allowing the reader to discriminate true negative from falsenegative results. The readout is objective and results are presented as positive, negative or indeterminate based on an algorithm. The test requires only one visit, obviating the dismal return rates found with TST reading. 10, 30 Although the IGRAs are promising, there are still some limitations: the method is only an indirect marker for MTB infection and distinguishes neither between latent and active infection nor between recent, past or treated MTB infection. The sensitivity for diagnosing active TB is sub-optimal, with false-negative results in both HIV-negative and -positive TB patients and otherwise immunocompromised individuals. 21, 22, [31] [32] [33] [34] [35] [36] [37] [38] IGRAs rely on functional CD4 + T cells [39] [40] [41] and their performance might be negatively influenced by low and impaired CD4 + cell counts in HIV-infected individuals. According to the manufacturer, the method is developed for the diagnosis of LTBI and is currently used to screen potentially infected individuals, but the evaluation is often performed in active TB as no gold standard is available for LTBI. 22, 32, 42 This article provides an overview of the knowledge available on the performance of the two commercially available IGRAs in adult HIV-positive individuals. We will focus on the sensitivity of the commercially available IGRAs; the positivity and indeterminate rates among HIV-positive and -negative individuals without active TB; the influence of CD4 + cell count on positivity and indeterminate rates; and discussion of the preliminary evidence for the predictive value of [4] [5] [6] [7] 9 We found eight published studies exploring the sensitivity of the commercially available IGRAs in HIV-positive individuals with active TB (see Table 1 ). [43] [44] [45] [46] [47] [48] [49] [50] The gold standard for active TB was either a positive culture or a microscopy-positive sputum smear.
The overall sensitivity of the TST in six studies was 43% (range 25-85%, 95% CI 37-49.5). 29, 43, 44, 46, 50 Compared with the TST, both IGRAs had an equal or higher sensitivity but with marked differences between the studies (see Table 1 ). Table 1 ).
Two studies compared QFT-IT with the TST in populations similar in respect of CD4 + cell count and who were antiretroviral treatment (ART)-naïve. 44 , 46 Tsiouris et al. found that the sensitivity of the IGRA was similar to the TST (81 and 85%, respectively), 44 whereas Raby et al.
showed a markedly increased sensitivity of QFT-IT compared with the TST (87 and 55%, respectively). 46 Only two studies, comprising 26 patients, addressed the sensitivity of QFT and they found very different results. Given the impaired sensitivity and inability to discriminate between active and LTBI, IGRAs should not be used as an alternative to conventional microbiological and clinical investigations in the diagnosis of active TB.
Association of Probable Latent Tuberculosis Infection and Positive Interferon-gamma Release Assays
To establish the accuracy of IGRA in LTBI, investigators have used either TST as the gold standard or association with risk factors for TB infection such as exposure. 72, 73 Using the latter approach, most studies in lowendemic regions find a higher agreement between IGRA positivity and clinical or epidemiological risk factors associated with LTBI than the TST, 35, 60, 73 and we have previously demonstrated in a low-endemic region that QFT and QFT-IT positivity was associated with long-term residency in high-endemic regions and with previous TB exposure, 35, 56, 74 whereas
TST positivity was independent of TB risk factors. 35, 75 Table 2 gives an overview of the IGRA and TST positivity rates in HIV-positive andnegative individuals without active TB. In high-and low-endemic regions, overall IGRA positivity rates ranged from 39 to 68% and 5.3 to 13.2%, respectively, underlining the specificity of the tests. Exclusion of indeterminate results did not change the result (not shown). In contrast to the observation of impaired sensitivity for HIV-positive individuals in active TB (see Table 1 ) we did not see such clear differences in otherwise healthy HIV-positive individuals (see Table 2 ). In only four studies was a direct head-to-head comparison between the T-spot and the QFT or QFT-IT performed, reporting only a poor inter-test agreement (κ range 0.06-0.34). 49, 51, 55, 57 The clinical relevance of this difference between the IGRAs remains to be elucidated.
Indeterminate Results
Indeterminate rates in active TB were higher (see Table 1 ) than in healthy controls, consistent with other observations demonstrating reduced T-cell reactivity in patients with severe TB. 75, 77 The general perception is that T-spot seems to be more sensitive, especially in immunocompromised individuals, in comparison with the QFT/QFT-IT. We found a trend for higher sensitivity of the T-spot compared with QFT-IT in active TB, mainly explained by higher QFT-IT indeterminate rates (see Table 1 ), whereas the overall positivity rate in individuals with possible LTBI for both IGRAs was similar (see Table 2 ).
The overall rate of indeterminate results in individuals screened for LTBI was 4% (range 0.4-43.5%, 95% CI 1.8-4.7%), 4% (range 2-6%, 95% CI 3.5-5%) and 6.7% (range 1-14%, 95% CI 5.5-9%) for the QFT, QFT-IT and the T-spot, respectively. Five studies compared both IGRAs, with conflicting results: four studies found a higher rate of indeterminate T-spot results compared with the QFT/QFT-IT in active TB 48, 49 or probable LTBI (see Tables 1 and 2) 49 in screening for LTBI in high-endemic settings (see Table 2 ).
Impact of CD4 + Cell Count on Interferongamma Release Assay Performance
Several studies have evaluated the association between CD4 + cell count and indeterminate rates. Of 16 studies, two were biased in respect of CD4 + cell counts: patients with <100 CD4 + cells/μl were excluded or infrequent. 58, 60 Fourteen of the 16 studies that addressed the effect of CD4 count on IGRA performances reported a trend towards a lower phytohaemagglutinin (PHA)-induced IFN-γ response with decreasing CD4 + cell count irrespective of the IGRA used, in addition looking at the consecutively increased risk of indeterminate results in association with CD4 + cell count; the effect seems to be more marked for the QFT/QFT-IT than for the T-spot, although most studies did not perform a direct head-to-head comparison. 47 However, the number of patients with active TB is limited and results between studies diverge.
The higher rate of indeterminate results in patients with active HIV-TB co-infection can partly be explained by the lower mean/median CD4 + cell count, but an increased T-cell exhaustion due to the concomitant active HIV/TB co-infection might be an additional important factor influencing the rate of indeterminate results.
The most consistent results were found in HIV-positive patients without active TB, where an increasing rate of indeterminate results was found in patients with lower CD4 + T-cell counts (see Table 3 ). Overall indeterminate QFT-IT rates (n=2151) in patients with <100 and 100-200 CD4 + cells/μl were 15 and 8.5%, respectively, whereas the rate of indeterminate results in patients with CD4 + cells >200 cells/μl was 2.5% (see Table 3 ). For the T-spot (n=908), overall indeterminate rates were 16.5 and 11.5% for patients with CD4 + cell counts <100 and 100-200 cells/μl, respectively, and 6% among those with CD4 + cell count >200 cells/μl (see Table 3 ).
Thus, from these studies, the rate of indeterminate results in HIV-positive individuals with CD4 cell count >200 cells/μl is comparable to that reported from non-HIV-infected individuals, 22, 83 with no significant difference between the two IGRAs. Interestingly, we did not find a difference between the IGRAs in patients with low CD4 + cell counts <200 or <100 cells/μl in terms of indeterminate results (see Table 3 ). It has previously been suggested that the T-spot might be more sensitive in very low CD4 + cell counts, because in contrast to the whole blood assay (QFT/QFT-IT) the T-spot is based on purified lymphocytes and cell numbers are quantitatively adjusted before incubation, which is thought to ensures a higher sensitivity by reducing the impact of lymphopenia and diurnal changes in number of circulating cells. [78] [79] [80] [81] However, because of the variations between the studies and the limited number of patients with very low CD4 + cell counts (see Table 3 ), we could not confirm this hypothesis and should not draw any definite conclusions.
Irrespective of the IGRA used, several studies find 46, 50, 52, 58 that the likelihood of positive results decreases with CD4 + cell count and diminished levels of antigen-specific-IFN-γ production, which raises concerns about increasing rates of false-negative IGRA results with decreasing CD4 + cell counts. In Aabye et al. 47 we found no effect of CD4 decline on the rate of false-negatives after exclusion of indeterminate rates, but studies with more patients in each CD4 stratum are needed in order to determine to what extent a decline in CD4 + cells affects the false-negative/sensitivity rate or only the indeterminate rate.
Some attempts have been made to adjust for low CD4 + cell counts.
Rangaka et al. 51 found a better test performance by correcting the TBspecific IFN-γ response by CD4 + T-cell count, and a similar observation for the T-spot was made by Clark et al. 61 in a mixed population of HIVpositive patients. Goletti et al. 82 found no improvement using the corrected values by actual CD4 + cell count for the T-spot in a low-TBendemic region.
Several publications have indicated that not only the absolute CD4 + cell number is of importance for test accuracy but also the nadir CD4 + cell counts. Dheda et al. 59 T-spot Median 361 (range 15-784) 3% 0% (4)) 0% (7) 5.5% (18) Leidl et al. 49 T-spot Median 283 (N/A) 3.5% 0% (10) 8.5% (23) 2.5% (76) Rangaka et al. 51 T-spot Median 392 (IQR 263;520) 1% 25% (4) 0% (6) 0% (54) Hoffmann et al. 60 T-spot Median 406 (range 50-1,080) 9.5% 0% (2) 11% (9) 9.5% (74) Stephan et al. 57 T-spot Median 408 (range 7-1,510) 3% 0% (14) 7% (28) 2.5% (244) Talati et al. 55 T Table 2 ;
c. Individuals with active tuberculosis (TB) excluded. QFT = QuantiFERON Gold; QFT-IT = QuantiFERON Gold InTube; T-spot = T-spot.TB.
in patients with low CD4 + T-cell nadir even after successful ART initiation 
Positive Predictive Value
Several studies have demonstrated that a positive TST result is associated with subsequent development of active TB. 9,13-15 Elzi et al.
found in a low-endemic setting (Switzerland) a significantly higher rate of consecutive active TB in HIV-positive individuals tested TSTpositive; however, the TST had a negative predictive value <100%.
9
A study following exposed contacts in a TB low-endemic setting found a progression rate to active TB in QFT-IT-positive individuals of 14.6% compared with 2.3% in individuals tested TST-positive. 83 The largest prospective study, conducted in the Gambia, used in-house ELISPOT and found an increased risk of developing active TB in IGRA-positive HIV-positive and -negative individuals but a poor negative predictive value, indicating either low sensitivity or high risk of new infection during follow-up. 84 Small studies in HIV-positive individuals from lowendemic regions have reported progression rates to active TB in HIVinfected QFT-GIT-positive individuals of two in 27 (7.4%) 56 and two in 20 (10%). 53 The largest study in a low-endemic region was by Aichelburg 
Improvement of Interferon-gamma Release Assays
A major challenge is to improve the accuracy of these assays for patients with immuno-suppression. 
Summary
The main conclusion of this article is that the sensitivity of IGRAs in HIV/TB co-infected individuals with or without indeterminate results is impaired compared with in HIV-negative patients with TB.
Indeterminate rates are higher in HIV-positive individuals and the number of CD4 + cells is significantly associated with the rate of indeterminate results, whereas the effect of CD4 + cell numbers on actual sensitivity is less pronounced. We were not able to confirm the previous hypothesis that T-spot is more accurate than QFT-IT in HIV-positive individuals. In HIV-positive individuals without active TB, the overall rate of positive results varied depending on country of origin, confirming the high specificity of the tests.
Minor differences between the IGRAs were found, but we were not able to explain them by differences in sensitivity, specificity or hostrelated factors. The evaluation of the currently published studies on
IGRAs is flawed by the heterogeneity of the studies summarised here. In low-endemic regions the negative predictive value in a well-treated HIV population is very high, whereas negative predictive value seems sub-optimal in a high-endemic settings, 
